GlassScriptPhysician profile
Alan C Yeung
NPI 1700920139
$78,860.70
in general payments reported to CMS, 2019-2025
13 companies · $3,431 in 2025
The $3,431 reported for 2025 was more than what 77% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $30K · 2020: $9,522 · 2021: $9,120 · 2022: $19K · 2023: $629 · 2024: $7,906 · 2025: $3,431.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $7,288 · Travel and Lodging: $1,599 · Food and Beverage: $1,580 · Consulting Fee: $1,500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $7,287.50 |
| Travel and Lodging | $1,598.75 |
| Food and Beverage | $1,579.58 |
| Consulting Fee | $1,500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $31,235.46 | 2019-2024 | |
| Medtronic Vascular, INC. | $15,828.95 | 2019-2020 | |
| Philips North America LLC | $11,495.93 | 2019 | |
| Medtronic, INC. | $10,863.19 | 2021-2025 | Corevalve Evolut R, Ensemble Ll, Apollotm |
| Edwards Lifesciences Corporation | $5,354.01 | 2019-2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Histosonics, INC. | $1,560.95 | 2025 | |
| Cordis US Corp. | $1,537.80 | 2025 | Emerald |
| Abbott Laboratories | $468.89 | 2019-2021 | |
| Ge Healthcare | $210.00 | 2019 | |
| Novartis Pharmaceuticals Corporation | $149.06 | 2023-2024 | Leqvio |
| Merck Sharp & Dohme LLC | $99.89 | 2023 | Verquvo |
| Cardiva Medical, INC. | $44.63 | 2024 | Savvywire |
| Cardiovascular Systems INC. | $11.94 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Yeung listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.